首页>投融资

Kyverna

上市

Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases.In August 2023, Kyverna Therapeutics Inc an oversubscribed $60 million Series B financing round bringing total Series B financing round to $145 million.In January 2022, Kyverna Therapeutics closed an oversubscribed $85 million Series B financing round led by Northpond Ventures;Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

https://kyvernatx.com/

470211

基本信息

公司全称

Kyverna Therapeutics Inc
类型

免疫细胞疗法开发商
产业领域

医药研发/制造、化学&生物药、其他
公司人数

51~100人
地址

5980 Horton St,STE 550 EMERYVILLE CALIFORNIA 94608; US;
联系电话

1-510-9252492
邮箱

info@kyvernatx.com
成立时间

2018-01-01

投融资

2024-02-08

上市

2.97亿美元

未透露
2023-08-03

B轮

1.45亿美元

jVen Capital

洲嶺资本

CAM Capital

Insight Partners

RTW Investments

Northpond Ventures

Vida Ventures

Westlake Village BioPartners

Gilead Sciences

GordonMD Global Investments

Bain Capital

Hudson Bay Capital

Argentum Peak

IntelliaTherapeutics

HealthCor
2020-01-14

A轮

2500万美元

Westlake Village BioPartners

Vida Ventures

Gilead Sciences

Kyverna

基本信息

投融资

相关投融资企业